Adam del Corral

426 total citations
5 papers, 332 citations indexed

About

Adam del Corral is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Adam del Corral has authored 5 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Adam del Corral's work include Prostate Cancer Treatment and Research (3 papers), PARP inhibition in cancer therapy (3 papers) and Cardiac electrophysiology and arrhythmias (1 paper). Adam del Corral is often cited by papers focused on Prostate Cancer Treatment and Research (3 papers), PARP inhibition in cancer therapy (3 papers) and Cardiac electrophysiology and arrhythmias (1 paper). Adam del Corral collaborates with scholars based in United States, France and United Kingdom. Adam del Corral's co-authors include Alice Huntsman-Labed, Catherine Dutreix, Ron Paquette, Thomas Fischer, Gary J. Schiller, Richard M. Stone, Jörge E. Cortes, Gerhard Ehninger, Daniel J. DeAngelo and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Leukemia.

In The Last Decade

Adam del Corral

5 papers receiving 328 citations

Peers

Countries citing papers authored by Adam del Corral

Since Specialization

Citations

This map shows the geographic impact of Adam del Corral's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam del Corral with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam del Corral more than expected).

Fields of papers citing papers by Adam del Corral

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam del Corral. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam del Corral. The network helps show where Adam del Corral may publish in the future.

Co-authorship network of co-authors of Adam del Corral

This figure shows the co-authorship network connecting the top 25 collaborators of Adam del Corral. A scholar is included among the top collaborators of Adam del Corral based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam del Corral. Adam del Corral is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. 2023 ·Journal of Clinical Oncology ·Elena Castro, Kim N., Shahneen Sandhu, David Olmos, Gerhardt Attard, Marniza Saad, Andrea Juliana Gomes, Dana E. Rathkopf, Matthew R. Smith, Taek Won Kang, Felipe Melo Cruz, Umberto Basso, Gary Mason, Adam del Corral, Shiva Dibaj, Daphne Wu, Brooke Diorio, (unknown), Deniz Tural, Eric J. Small	4
2	Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. 2022 ·Journal of Clinical Oncology ·Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea Juliana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Żurawski, V.S. Sakalo, Gary Mason, Adam del Corral, George Wang, Daphne Wu, Brooke Diorio, (unknown), Shahneen Sandhu	81
3	Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) patients 2022 ·Cancer Research ·Karen Urtishak, Gerhardt Attard, Tokuwa Kanno, Shibu Thomas, Gary Mason, Byron M. Espina, Eugene Zhu, Natalie A. Hutnick, Mary Guckert, Adam del Corral, Mark Li, Angela Lopez‐Gitlitz, Kim Chi, William Kevin Kelly, Evan Y. Yu, Karim Fizazi, Matthew R. Smith	2
4	Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia 2012 ·Leukemia ·Richard M. Stone, Thomas Fischer, Ron Paquette, Gary J. Schiller, Charles A. Schiffer, Gerhard Ehninger, Jörge E. Cortes, Hagop M. Kantarjian, Daniel J. DeAngelo, Alice Huntsman-Labed, Catherine Dutreix, Adam del Corral, Francis J. Giles	228
5	Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers 2012 ·Cancer Chemotherapy and Pharmacology ·Adam del Corral, Catherine Dutreix, Alice Huntsman-Labed, (unknown), Joel Morganroth, (unknown), Yanfeng Wang	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact